Sugi Predict

Sugi Predict / Compounds / SCHEMBL288636

SCHEMBL288636

SCHEMBL288636

Nc1cccc(C[C@H](N)C(=O)O)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 9/20 0.67
▸ PTGS1 P23219 2/20 0.67
▸ ALPI P09923 1/20 0.67
▸ PKM P14618 1/20 0.67
▸ XIAP P98170 1/20 0.67
▸ GRIA2 P42262 1/20 0.62
▸ NOS3 P29474 3/20 0.60
▸ NOS1 P29475 3/20 0.60
▸ NOS2 P35228 3/20 0.60
▸ KDM4E B2RXH2 1/20 0.57
▸ USP2 O75604 1/20 0.57
▸ EGFR P00533 1/20 0.57
▸ LCK P06239 1/20 0.57
▸ FYN P06241 1/20 0.57
▸ ADORA3 P0DMS8 1/20 0.57
▸ ALOX15 P16050 1/20 0.57
▸ HTR2A P28223 1/20 0.57
▸ PTGS2 P35354 1/20 0.57
▸ RECQL P46063 1/20 0.57
▸ HIF1A Q16665 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29475725 1.00 SLC7A5 (0.67) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL288729 1.00 SLC7A5 (0.67) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL385392 1.00 SLC7A5 (0.67) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL2314258 0.89 SLC7A5 (0.77) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL10888031 0.84 SLC7A5 (0.46) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL29217053 0.84 GRIA2 (0.84) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL944210 0.84 GRIA2 (0.84) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL6377902 0.83 MAOA (0.55) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL31370062 0.83 MAOA (0.55) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL31370551 0.82 GRIA2 (0.58) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577575-B2 Methods and compositions for promoting non-natural amino acid-containing protein production AMBRX, INC. (US) 2026-03-17 — — US claimed
US-12404512-B2 Method for optimizing antibody expression AMBRX, INC. (US) 2025-09-02 — — US claimed
EP-3788149-B1 A METHOD FOR OPTIMIZING ANTIBODY EXPRESSION AMBRX INC (US) 2025-08-27 — — EP claimed
CN-119455003-A Compositions, methods and uses comprising antibody-TLR agonist conjugates AMBRX公司 2025-02-18 — — CN claimed
CN-119455004-A Compositions, methods and uses comprising antibody-TLR agonist conjugates AMBRX公司 2025-02-18 — — CN claimed
CN-119410678-A Method for optimizing antibody expression AMBRX公司 2025-02-11 — — CN claimed
CN-112313336-B Method for optimizing antibody expression AMBRX公司 2024-12-03 — — CN claimed
EP-4461318-A2 NOVEL ANTI-PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY DRUG CONJUGATES Ambrx, Inc. (US) 2024-11-13 — — EP claimed
US-20240350835-A1 HUMANIZED ANTI-PROSTATE -SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY DRUG CONJUGATES AMBRX, INC. (US) 2024-10-24 — — US claimed
WO-2024215515-A1 DRUG LINKERS AND ANTIBODY CONJUGATES THEREOF AMBRX, INC. (US) 2024-10-17 — — WO claimed
WO-2011014973-A2 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2011-02-10 — — WO claimed
EP-1753719-B1 SUBSTITUTED PYRROLIDINE-2-ONES NOVARTIS AG (CH) 2010-03-03 — — EP claimed
EP-1991572-A2 PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN SYNTONIX PHARMACEUTICALS, INC. (US) 2008-11-19 — — EP claimed
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn BIOGEN HEMOPHILIA INC. 2007-11-01 — — US claimed
WO-2007098420-A2 PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN SYNTONIX PHARMACEUTICALS, INC. (US) 2007-08-30 — — WO claimed
US-20070172421-A1 Substituted pyrrolidine-2-ones NOVARTIS AG (CH) 2007-07-26 — — US claimed
CN-1960971-A Substituted pyrrolidine-2-ones NOVARTIS AG (CH) 2007-05-09 — — CN claimed
US-20050119190-A1 Inhibitors of the blood-clotting factor xa, production thereof and use of the same CURACYTE AG (DE) 2005-06-02 — — US claimed
EP-1483285-A1 INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME Curacyte AG (DE) 2004-12-08 — — EP claimed
WO-2003076457-A1 INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME CURACYTE AG (DE) 2003-09-18 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119190-A1 Inhibitors of the blood-clotting factor xa, production thereof and use of the same SERPINC1, TFPI, F11 SLC7A5 4712/4885PTGS1 1407/4885ALPI 2075/4885
US-12577575-B2 Methods and compositions for promoting non-natural amino acid-containing protein production AARS1, NSUN3, UPF1 SLC7A5 136/4885PTGS1 4736/4885ALPI 2459/4885
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn FCGRT, FCGR3B, FCGR1A SLC7A5 1904/4885PTGS1 2032/4885ALPI 3829/4885
US-20070172421-A1 Substituted pyrrolidine-2-ones PRLHR, EPOR, FLT1 SLC7A5 596/4885PTGS1 1759/4885ALPI 3360/4885
US-20240350835-A1 HUMANIZED ANTI-PROSTATE -SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY DRUG CONJUGATES FOLH1, KLK3, PSMA6 SLC7A5 1803/4885PTGS1 2436/4885ALPI 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.